1. Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open‐label randomized comparative pilot clinical study. (26th September 2019) Authors: Alex, P.; Williams, S.; Sutton, L.; Yesudas, T.; Sutton, C.; Thomas, S.; Centola, M. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 3(2020) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open‐label randomized comparative pilot clinical study. (1st April 2020) Authors: Alex, P.; Williams, S.; Sutton, L.; Yesudas, T.; Sutton, C.; Thomas, S.; Centola, M. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 3(2020) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0132 A multi-biomarker disease activity score (the vectra DA algorithm score) reflects clinical remission for rheumatoid arthritis (RA) in the best study. (23rd January 2014) Authors: Hirata, S.; Dirven, L.; Cavet, G.; Centola, M.; Lems, W.F.; Tanaka, Y.; Huizinga, T.W.; Allaart, C.F. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗